Marc Hedrick; President & CEO; Plus Therapeutics, Inc. Andrew Sims; VP & CFO; Plus Therapeutics, Inc. Norman LaFrance; SVP & Chief Medical Officer; Plus Therapeutics ...
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript March 5, 2024 Plus Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.7, expectations were $-0.78.
The investment firm also called Janux well-capitalized, with around $345M at the end of Q4 plus an approximately $300M equity raise in February. “As a leader in this emerging and now highly ...
Plus Therapeutics PSTV reported its Q4 earnings results on Tuesday, March 5, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Plus Therapeutics beat estimated earnings ...
Thank you for standing by, and welcome to the 5N Plus Inc. Fourth Quarter 2023 Results ... and thank you for joining us for our Q4 and full year 2023 results conference call and webcast.
Marc Hedrick; President & CEO; Plus Therapeutics, Inc. Andrew Sims; VP & CFO; Plus Therapeutics, Inc. Norman LaFrance; SVP & Chief Medical Officer; Plus Therapeutics ...
Marc Hedrick; President & CEO; Plus Therapeutics, Inc. Andrew Sims; VP & CFO; Plus Therapeutics, Inc. Norman LaFrance; SVP & Chief Medical Officer; Plus Therapeutics ...
Paramount Global’s earnings in the fourth quarter edged Wall Street forecasts, but a double-digit slide in advertising dragged down total revenue by 6%. Revenue came in at $7.6 billion, while ...
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $2.40 per share a year ago. These figures ...